JPH11508768A - ウイルス粒子産生カプセル化細胞 - Google Patents
ウイルス粒子産生カプセル化細胞Info
- Publication number
- JPH11508768A JPH11508768A JP9504165A JP50416597A JPH11508768A JP H11508768 A JPH11508768 A JP H11508768A JP 9504165 A JP9504165 A JP 9504165A JP 50416597 A JP50416597 A JP 50416597A JP H11508768 A JPH11508768 A JP H11508768A
- Authority
- JP
- Japan
- Prior art keywords
- cells
- cell
- encapsulated
- sulfate
- gene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000700605 Viruses Species 0.000 title claims abstract description 64
- 239000002245 particle Substances 0.000 title claims abstract description 58
- 230000001177 retroviral effect Effects 0.000 claims abstract description 35
- 238000004519 manufacturing process Methods 0.000 claims abstract description 24
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 17
- 239000013603 viral vector Substances 0.000 claims abstract description 11
- 108700026220 vif Genes Proteins 0.000 claims abstract description 3
- 210000004027 cell Anatomy 0.000 claims description 229
- 108090000623 proteins and genes Proteins 0.000 claims description 74
- 239000002775 capsule Substances 0.000 claims description 72
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate group Chemical group S(=O)(=O)([O-])[O-] QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 53
- 239000013598 vector Substances 0.000 claims description 43
- 229920002678 cellulose Polymers 0.000 claims description 31
- 239000001913 cellulose Substances 0.000 claims description 31
- 239000003094 microcapsule Substances 0.000 claims description 24
- 150000004676 glycans Chemical class 0.000 claims description 21
- 229920001282 polysaccharide Polymers 0.000 claims description 21
- 239000005017 polysaccharide Substances 0.000 claims description 21
- 102000004169 proteins and genes Human genes 0.000 claims description 18
- 238000001556 precipitation Methods 0.000 claims description 17
- 239000007864 aqueous solution Substances 0.000 claims description 16
- 238000004806 packaging method and process Methods 0.000 claims description 16
- 108010005774 beta-Galactosidase Proteins 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 14
- 239000013604 expression vector Substances 0.000 claims description 13
- 229920000642 polymer Polymers 0.000 claims description 12
- 239000003550 marker Substances 0.000 claims description 11
- 210000000056 organ Anatomy 0.000 claims description 11
- 229920000867 polyelectrolyte Polymers 0.000 claims description 11
- 239000011148 porous material Substances 0.000 claims description 10
- 125000001453 quaternary ammonium group Chemical group 0.000 claims description 10
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 9
- 102000005936 beta-Galactosidase Human genes 0.000 claims description 9
- 210000005075 mammary gland Anatomy 0.000 claims description 9
- 229910052708 sodium Inorganic materials 0.000 claims description 9
- 239000011734 sodium Substances 0.000 claims description 9
- 125000001273 sulfonato group Chemical group [O-]S(*)(=O)=O 0.000 claims description 8
- 229920001059 synthetic polymer Polymers 0.000 claims description 8
- 230000015572 biosynthetic process Effects 0.000 claims description 7
- 241001430294 unidentified retrovirus Species 0.000 claims description 7
- 239000000243 solution Substances 0.000 claims description 6
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 5
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 claims description 5
- 108090000695 Cytokines Proteins 0.000 claims description 5
- 229930193140 Neomycin Natural products 0.000 claims description 5
- 229920002472 Starch Polymers 0.000 claims description 5
- 108020004440 Thymidine kinase Proteins 0.000 claims description 5
- PZAGQUOSOTUKEC-UHFFFAOYSA-N acetic acid;sulfuric acid Chemical compound CC(O)=O.OS(O)(=O)=O PZAGQUOSOTUKEC-UHFFFAOYSA-N 0.000 claims description 5
- 239000007975 buffered saline Substances 0.000 claims description 5
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 5
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 5
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 5
- 229920002301 cellulose acetate Polymers 0.000 claims description 5
- 229960004927 neomycin Drugs 0.000 claims description 5
- 229920001467 poly(styrenesulfonates) Polymers 0.000 claims description 5
- 229960002796 polystyrene sulfonate Drugs 0.000 claims description 5
- 239000011970 polystyrene sulfonate Substances 0.000 claims description 5
- 239000008107 starch Substances 0.000 claims description 5
- 235000019698 starch Nutrition 0.000 claims description 5
- 239000000725 suspension Substances 0.000 claims description 5
- 102000000588 Interleukin-2 Human genes 0.000 claims description 4
- 108010002350 Interleukin-2 Proteins 0.000 claims description 4
- 102000006601 Thymidine Kinase Human genes 0.000 claims description 4
- 239000011159 matrix material Substances 0.000 claims description 4
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 claims description 4
- 102000007698 Alcohol dehydrogenase Human genes 0.000 claims description 3
- 108010021809 Alcohol dehydrogenase Proteins 0.000 claims description 3
- 108020004774 Alkaline Phosphatase Proteins 0.000 claims description 3
- 108050004290 Cecropin Proteins 0.000 claims description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 3
- 102000004127 Cytokines Human genes 0.000 claims description 3
- 102000000311 Cytosine Deaminase Human genes 0.000 claims description 3
- 108010080611 Cytosine Deaminase Proteins 0.000 claims description 3
- 108010036176 Melitten Proteins 0.000 claims description 3
- 241001465754 Metazoa Species 0.000 claims description 3
- 108700005075 Regulator Genes Proteins 0.000 claims description 3
- 241000700584 Simplexvirus Species 0.000 claims description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 3
- 230000001028 anti-proliverative effect Effects 0.000 claims description 3
- 210000004369 blood Anatomy 0.000 claims description 3
- 239000008280 blood Substances 0.000 claims description 3
- 230000022131 cell cycle Effects 0.000 claims description 3
- 229960000633 dextran sulfate Drugs 0.000 claims description 3
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 claims description 3
- VDXZNPDIRNWWCW-JFTDCZMZSA-N melittin Chemical compound NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(N)=O)CC1=CNC2=CC=CC=C12 VDXZNPDIRNWWCW-JFTDCZMZSA-N 0.000 claims description 3
- 210000000496 pancreas Anatomy 0.000 claims description 3
- 102000002260 Alkaline Phosphatase Human genes 0.000 claims description 2
- 241000283690 Bos taurus Species 0.000 claims description 2
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 claims description 2
- 230000000259 anti-tumor effect Effects 0.000 claims description 2
- 210000001367 artery Anatomy 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 230000001605 fetal effect Effects 0.000 claims description 2
- 239000008103 glucose Substances 0.000 claims description 2
- 229950010131 puromycin Drugs 0.000 claims description 2
- 210000000329 smooth muscle myocyte Anatomy 0.000 claims description 2
- 238000005507 spraying Methods 0.000 claims description 2
- 239000002131 composite material Substances 0.000 claims 2
- -1 diallyl ammonium Chemical compound 0.000 claims 2
- 108010078814 Tumor Suppressor Protein p53 Proteins 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- YOUGRGFIHBUKRS-UHFFFAOYSA-N benzyl(trimethyl)azanium Chemical compound C[N+](C)(C)CC1=CC=CC=C1 YOUGRGFIHBUKRS-UHFFFAOYSA-N 0.000 claims 1
- 239000005518 polymer electrolyte Substances 0.000 claims 1
- MLGWTHRHHANFCC-UHFFFAOYSA-N prop-2-en-1-amine;hydrochloride Chemical compound Cl.NCC=C MLGWTHRHHANFCC-UHFFFAOYSA-N 0.000 claims 1
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 claims 1
- 229920002554 vinyl polymer Polymers 0.000 claims 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000013612 plasmid Substances 0.000 description 17
- 206010028980 Neoplasm Diseases 0.000 description 15
- 239000002609 medium Substances 0.000 description 13
- 210000001519 tissue Anatomy 0.000 description 13
- 235000018102 proteins Nutrition 0.000 description 12
- 239000012634 fragment Substances 0.000 description 11
- 208000015181 infectious disease Diseases 0.000 description 10
- 238000001638 lipofection Methods 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- 230000001105 regulatory effect Effects 0.000 description 9
- 239000012679 serum free medium Substances 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 238000002054 transplantation Methods 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical class CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 238000013459 approach Methods 0.000 description 6
- 230000028993 immune response Effects 0.000 description 6
- 230000003612 virological effect Effects 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 241000714177 Murine leukemia virus Species 0.000 description 5
- 239000011543 agarose gel Substances 0.000 description 5
- 210000000481 breast Anatomy 0.000 description 5
- 238000005538 encapsulation Methods 0.000 description 5
- 238000001415 gene therapy Methods 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 229910021653 sulphate ion Inorganic materials 0.000 description 5
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 4
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 description 4
- 102000003960 Ligases Human genes 0.000 description 4
- 108090000364 Ligases Proteins 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- 238000010240 RT-PCR analysis Methods 0.000 description 4
- 108010067390 Viral Proteins Proteins 0.000 description 4
- 239000006143 cell culture medium Substances 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 210000000987 immune system Anatomy 0.000 description 4
- 230000002458 infectious effect Effects 0.000 description 4
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 108010020076 Cytochrome P-450 CYP2B1 Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 241000713333 Mouse mammary tumor virus Species 0.000 description 3
- 206010028851 Necrosis Diseases 0.000 description 3
- 238000010222 PCR analysis Methods 0.000 description 3
- 108020000999 Viral RNA Proteins 0.000 description 3
- 230000033115 angiogenesis Effects 0.000 description 3
- 238000003501 co-culture Methods 0.000 description 3
- 238000001493 electron microscopy Methods 0.000 description 3
- 238000012869 ethanol precipitation Methods 0.000 description 3
- 210000003494 hepatocyte Anatomy 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000028709 inflammatory response Effects 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 230000017074 necrotic cell death Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 210000002845 virion Anatomy 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 2
- 238000007400 DNA extraction Methods 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 102000001301 EGF receptor Human genes 0.000 description 2
- 108060006698 EGF receptor Proteins 0.000 description 2
- 229920000209 Hexadimethrine bromide Polymers 0.000 description 2
- 102000018251 Hypoxanthine Phosphoribosyltransferase Human genes 0.000 description 2
- 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 2
- 108010025020 Nerve Growth Factor Proteins 0.000 description 2
- 102000015336 Nerve Growth Factor Human genes 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 2
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 2
- 102000006382 Ribonucleases Human genes 0.000 description 2
- 108010083644 Ribonucleases Proteins 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 2
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 2
- 101710087237 Whey acidic protein Proteins 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- WQZGKKKJIJFFOK-FPRJBGLDSA-N beta-D-galactose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-FPRJBGLDSA-N 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 239000013599 cloning vector Substances 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 238000010924 continuous production Methods 0.000 description 2
- 229960004397 cyclophosphamide Drugs 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 239000002254 cytotoxic agent Substances 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 229960001101 ifosfamide Drugs 0.000 description 2
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 230000002601 intratumoral effect Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000004626 scanning electron microscopy Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 102000003390 tumor necrosis factor Human genes 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- DFUSDJMZWQVQSF-XLGIIRLISA-N (2r)-2-methyl-2-[(4r,8r)-4,8,12-trimethyltridecyl]-3,4-dihydrochromen-6-ol Chemical compound OC1=CC=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1 DFUSDJMZWQVQSF-XLGIIRLISA-N 0.000 description 1
- KZMAWJRXKGLWGS-UHFFFAOYSA-N 2-chloro-n-[4-(4-methoxyphenyl)-1,3-thiazol-2-yl]-n-(3-methoxypropyl)acetamide Chemical compound S1C(N(C(=O)CCl)CCCOC)=NC(C=2C=CC(OC)=CC=2)=C1 KZMAWJRXKGLWGS-UHFFFAOYSA-N 0.000 description 1
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 101100329226 Bacillus anthracis cpfC1 gene Proteins 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 108010052832 Cytochromes Proteins 0.000 description 1
- 102000018832 Cytochromes Human genes 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 241000255925 Diptera Species 0.000 description 1
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000929495 Homo sapiens Adenosine deaminase Proteins 0.000 description 1
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 1
- 102000002265 Human Growth Hormone Human genes 0.000 description 1
- 108010000521 Human Growth Hormone Proteins 0.000 description 1
- 239000000854 Human Growth Hormone Substances 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 1
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 1
- 102000008192 Lactoglobulins Human genes 0.000 description 1
- 108010060630 Lactoglobulins Proteins 0.000 description 1
- 101150053185 P450 gene Proteins 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 241000711517 Torovirus Species 0.000 description 1
- BZHJMEDXRYGGRV-UHFFFAOYSA-N Vinyl chloride Chemical compound ClC=C BZHJMEDXRYGGRV-UHFFFAOYSA-N 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 108700023471 alginate-polylysine-alginate Proteins 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- HOQPTLCRWVZIQZ-UHFFFAOYSA-H bis[[2-(5-hydroxy-4,7-dioxo-1,3,2$l^{2}-dioxaplumbepan-5-yl)acetyl]oxy]lead Chemical compound [Pb+2].[Pb+2].[Pb+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HOQPTLCRWVZIQZ-UHFFFAOYSA-H 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000003560 cancer drug Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 150000003841 chloride salts Chemical class 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 229960002086 dextran Drugs 0.000 description 1
- 238000012137 double-staining Methods 0.000 description 1
- 238000005868 electrolysis reaction Methods 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 1
- 229960002963 ganciclovir Drugs 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000001744 histochemical effect Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000005745 host immune response Effects 0.000 description 1
- 102000043395 human ADA Human genes 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 235000021243 milk fat Nutrition 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 229940053128 nerve growth factor Drugs 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229940116736 romycin Drugs 0.000 description 1
- FHHPUSMSKHSNKW-SMOYURAASA-M sodium deoxycholate Chemical compound [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 FHHPUSMSKHSNKW-SMOYURAASA-M 0.000 description 1
- JJICLMJFIKGAAU-UHFFFAOYSA-M sodium;2-amino-9-(1,3-dihydroxypropan-2-yloxymethyl)purin-6-olate Chemical compound [Na+].NC1=NC([O-])=C2N=CN(COC(CO)CO)C2=N1 JJICLMJFIKGAAU-UHFFFAOYSA-M 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 238000003153 stable transfection Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000008054 sulfonate salts Chemical class 0.000 description 1
- 238000000352 supercritical drying Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 229920003002 synthetic resin Polymers 0.000 description 1
- 239000000057 synthetic resin Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
- C12N11/02—Enzymes or microbial cells immobilised on or in an organic carrier
- C12N11/04—Enzymes or microbial cells immobilised on or in an organic carrier entrapped within the carrier, e.g. gel or hollow fibres
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
- C12N2740/13021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
- C12N2740/13041—Use of virus, viral particle or viral elements as a vector
- C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Dispersion Chemistry (AREA)
- Plant Pathology (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Manufacturing Of Micro-Capsules (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.細胞を含有するコアと該コアを包囲する多孔性カプセル壁とを含んでなる 、ウイルス粒子を産生するカプセル化細胞であって、該多孔性カプセル壁が該ウ イルス粒子を透過しうることを特徴とするカプセル化細胞。 2.該多孔性カプセル壁が、対荷電高分子電解質から形成される高分子電解質 複合体よりなる、請求項1に記載のカプセル化細胞。 3.該多孔性カプセル壁が、硫酸基含有多糖もしくは多糖誘導体またはスルホ ナート基含有合成ポリマーと第四級アンモニウム基を有するポリマーとから形成 される高分子電解質複合体よりなる、請求項1または2に記載のカプセル化細胞 。 4.該硫酸基含有多糖もしくは多糖誘導体が硫酸セルロース、酢酸硫酸セルロ ース、カルボキシメチルセルロース硫酸、デキストラン硫酸またはデンプン硫酸 であり、該スルホナート基含有合成ポリマーがポリスチレンスルホナートである 、請求項3に記載のカプセル化細胞。 5.第四級アンモニウム基を有するポリマーが、ポリジメチルジアリルアンモ ニウムまたはポリビニルベンジル−トリメチルアンモニウムである、請求項3に 記載のカプセル化細胞。 6.該多孔性カプセル壁が、硫酸セルロースおよびポリジメチルジアリルアン モニウムから形成される複合体よりなる、請求項1〜5のいずれか1項に記載の カプセル化細胞。 7.0.01〜5mm、好ましくは0.1〜1mmの直径を有するマイクロカプセルの形 態を有する、請求項1〜6のいずれか1項に記載のカプセル化細胞。 8.該カプセルが、孔を含有するカプセル表面に包囲される該カプセル壁の内 部を形成する海綿状硫酸セルロースマトリックスよりなり、該海綿状マトリック スが細胞で満たされている、請求項1〜7のいずれか1項に記載のカプセル化細 胞。 9.該多孔性カプセル壁の表面孔径が、80〜150nm、好ましくは100〜120nmで ある、請求項1〜8のいずれか1項に記載のカプセル化細胞。 10.該カプセル化細胞により産生されるウイルス粒子が、レトロウイルスベク ターのゲノムを含有するレトロウイルス粒子である、請求項1〜9のいずれか1 項に記載のカプセル化細胞。 11.レトロウイルス粒子を産生するカプセル化細胞が、発現ベクターでトラン スフェクションされたパッケージング細胞系であり、該発現ベクターが、レトロ ウイルスベクターコンストラクトを保持し、該レトロウイルスベクターコンスト ラクトが、標的細胞に感染し該標的細胞中で該レトロウイルスベクターコンスト ラクトに保持された1以上のコード配列の発現を指令する能力を有し、該パッケ ージング細胞系が、該レトロウイルスベクターコンストラクトのゲノムがパッケ ージングされるのに必要なタンパク質をコードする遺伝子を保持する少なくとも 1つの発現ベクターを含む、請求項10に記載のカプセル化細胞。 12.該コード配列の少なくとも1つが、マーカー遺伝子、治療用遺伝子、抗ウ イルス遺伝子、抗腫瘍遺伝子およびサイトカイン遺伝子から選ばれる異種ペプチ ドをコードする、請求項11に記載のカプセル化細胞。 13.該マーカー遺伝子が、β−ガラクトシダーゼ、ネオマイシン、アルコール デヒドロゲナーゼ、ピューロマイシン、ヒポキサンチンホスホリボシルトランス フェラーゼ(HPRT)、ハイグロマイシンおよび分泌アルカリホスファターゼな どのタンパク質をコードするマーカー遺伝子よりなる群から選ばれ、該治療用遺 伝子が、単純ヘルペスウイルスチミジンキナーゼ、シトシンデアミナーゼ、グア ニンホスホリボシルトランスフェラーゼ(gpt)、シトクロムP450などのタンパク 質をコードする遺伝子、SDIなどの細胞周期調節遺伝子、p53などのタンパク 質をコードする癌抑制遺伝子、メリチン、セクロピンまたはサイトカイン(例え ば、IL-2)などのタンパク質をコードする抗増殖遺伝子から選ばれる、請求項 12に記載のカプセル化細胞。 14.該パッケージング細胞系が、psi-2、psi-crypt、psi-AM、GP+E-86、 PA317およびGP+envAM-12から選ばれる、請求項11に記載のカプセル化細胞 。 15.該発現ベクターが、pBAG、pLXSN、p125LX、pLX2B1またはpc3 /2B1またはそれらの誘導体である、請求項11に記載のカプセル化細胞。 16.ウイルス粒子を産生する細胞を高分子電解質の水溶液に懸濁し、ついで前 形成粒子形態の該懸濁液を、対荷電高分子電解質の水溶液を含有する沈殿浴中に 導入することを含んでなる、請求項1〜15のいずれか1項に記載のカプセル化細 胞の製造法。 17.該粒子形成が噴霧により生じる、請求項16に記載の製造法。 18.該細胞を、硫酸基含有多糖もしくは多糖誘導体またはスルホナート基含有 合成ポリマーの水溶液に懸濁する、請求項16または17に記載の製造法。 19.該硫酸基含有多糖もしくは多糖誘導体が、硫酸セルロース、酢酸硫酸セル ロース、カルボキシメチルセルロース硫酸、デキストラン硫酸またはデンプン硫 酸であり、該スルホナート基含有合成ポリマーがポリスチレンスルホナートであ る、請求項18に記載の製造法。 20.該沈殿浴が、第四級アンモニウム基を有するポリマーの水溶液を含有する 、請求項16または17に記載の製造法。 21.第四級アンモニウム基を有するポリマーが、ポリジメチルジアリルアンモ ニウムまたはポリビニルベンジル−トリメチルアンモニウムである、請求項20に 記載の製造法。 22.該細胞を、硫酸セルロースナトリウムの水溶液に懸濁し、ポリジメチルジ アリルアンモニウムクロリドの水溶液を含有する沈殿浴中に導入する、請求項16 または17に記載の製造法。 23.該硫酸セルロース水溶液が、緩衝食塩水中の0.5〜50%、好ましくは2〜 5%の硫酸セルロースナトリウムおよび2〜10%、好ましくは5%のウシ胎児血 清よりなる、請求項22に記載の製造法。 24.該沈殿浴中の水溶液が、緩衝食塩水中の0.5〜50%、好ましくは2〜10% 、より好ましくは3%のポリジメチルジアリルアンモニウムクロリドよりなる、 請求項22に記載の製造法。 25.請求項16〜24のいずれか1項に記載の製造法により製造される、請求項1 〜15のいずれか1項に記載のカプセル化細胞。 26.標的器官/細胞へ遺伝子を輸送するための、請求項1〜15のいずれか1項 に記載のカプセル化細胞の使用であって、 a)適当な培地中で該カプセル化細胞を培養し、そして b)ヒトを含む生きた動物の体内へ該カプセル化細胞を移植することを含んで なる使用。 27.該標的器官/細胞が乳腺または膵臓である、請求項26に記載の使用。 28.該標的器官/細胞が、動脈を包囲する平滑筋細胞である、請求項26に記載 の使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DK0740/95 | 1995-06-27 | ||
DK74095 | 1995-06-27 | ||
PCT/EP1996/002748 WO1997001357A1 (en) | 1995-06-27 | 1996-06-24 | Encapsulated cells producing viral particles |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007301109A Division JP4848348B2 (ja) | 1995-06-27 | 2007-11-21 | ウイルス粒子産生カプセル化細胞 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH11508768A true JPH11508768A (ja) | 1999-08-03 |
JP4119952B2 JP4119952B2 (ja) | 2008-07-16 |
Family
ID=8097001
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP50416597A Expired - Lifetime JP4119952B2 (ja) | 1995-06-27 | 1996-06-24 | ウイルス粒子産生カプセル化細胞 |
JP2007301109A Expired - Lifetime JP4848348B2 (ja) | 1995-06-27 | 2007-11-21 | ウイルス粒子産生カプセル化細胞 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007301109A Expired - Lifetime JP4848348B2 (ja) | 1995-06-27 | 2007-11-21 | ウイルス粒子産生カプセル化細胞 |
Country Status (22)
Country | Link |
---|---|
US (1) | US6776985B1 (ja) |
EP (1) | EP0835137B1 (ja) |
JP (2) | JP4119952B2 (ja) |
KR (1) | KR100484883B1 (ja) |
CN (1) | CN1187095C (ja) |
AT (1) | ATE309000T1 (ja) |
AU (1) | AU708273B2 (ja) |
CA (1) | CA2222559A1 (ja) |
CZ (1) | CZ286979B6 (ja) |
DE (1) | DE69633180D1 (ja) |
DK (1) | DK0835137T3 (ja) |
ES (1) | ES2253754T3 (ja) |
HK (1) | HK1010139A1 (ja) |
IL (1) | IL122119A (ja) |
NO (1) | NO321427B1 (ja) |
NZ (1) | NZ312671A (ja) |
PL (1) | PL185338B1 (ja) |
PT (1) | PT835137E (ja) |
RU (1) | RU2187301C2 (ja) |
SI (1) | SI0835137T1 (ja) |
UA (1) | UA65525C2 (ja) |
WO (1) | WO1997001357A1 (ja) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK0817858T3 (da) | 1995-03-09 | 2003-08-11 | Gsf Forschungszentrum Umwelt | Vektorer, som indeholder terapeutiske gener for antimikrobielle peptider, til anvendelse ved genterapi |
ES2253754T3 (es) | 1995-06-27 | 2006-06-01 | Bavarian Nordic A/S | Celulas encapsuladas que producen particulas viricas. |
DE69730595D1 (de) | 1996-03-27 | 2004-10-14 | Bavarian Nordic As Kvistgaard | Verkapselte zellen expremierend cytochrome p450 für die aktivierung einer medikamentenvorstufe |
US6540995B1 (en) | 1996-03-27 | 2003-04-01 | Bavarian Nordic Research Institute Gmbh | Encapsulated cells producing cytochrome P450 |
CN1266362A (zh) | 1998-05-05 | 2000-09-13 | 皇家菲利浦电子有限公司 | 包括具有刷毛区和齿间刷毛区的毛刷件的牙刷 |
DE602005014354D1 (de) | 2004-03-30 | 2009-06-18 | Nsgene As | Therapeutische verwendung des wachstumsfaktors nsg33 |
US20090022785A1 (en) * | 2005-05-03 | 2009-01-22 | Veterinarmedizinische Universitat Wien | Permeable Capsules |
JP5456692B2 (ja) * | 2007-12-20 | 2014-04-02 | エシコン・インコーポレイテッド | カプセル化された腎臓組織 |
KR101250925B1 (ko) * | 2011-10-28 | 2013-04-04 | 한화케미칼 주식회사 | 캡슐 세포용 구조체 |
GB201408233D0 (en) | 2014-05-09 | 2014-06-25 | Austrianova Singapore Pte Ltd | Use of polyanionic composition |
WO2017089308A1 (en) * | 2015-11-24 | 2017-06-01 | Glaxosmithkline Intellectual Property Development Limited | Stable cell lines for retroviral production |
DE102016122317A1 (de) * | 2015-11-24 | 2017-05-24 | Glaxosmithkline Intellectual Property Development Limited | Transientes transfektionsverfahren für retrovirale produktion |
CN109153978B (zh) * | 2016-05-25 | 2022-12-06 | 隆萨休斯敦股份有限公司 | 使用聚二烯丙基二烷基铵盐分离腺相关病毒的方法 |
RU2688383C2 (ru) * | 2017-07-10 | 2019-05-21 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Саратовский национальный исследовательский государственный университет имени Н.Г. Чернышевского" | Способ синтеза белка в культуре бактериальных клеток |
CN110615667B (zh) * | 2018-06-19 | 2022-02-15 | 华北理工大学 | 基于铁尾矿和碱渣的核壳结构陶粒及其制备方法 |
JP2024519909A (ja) * | 2021-05-21 | 2024-05-21 | バイオナット ラブス リミテッド | マイクロボット媒介治療送達のためのシステム及び方法 |
CN115820683B (zh) * | 2022-09-28 | 2024-04-05 | 西南大学 | 家蚕Cyp9a20基因及其应用 |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4391909A (en) * | 1979-03-28 | 1983-07-05 | Damon Corporation | Microcapsules containing viable tissue cells |
DD160393A3 (de) * | 1980-11-14 | 1983-07-27 | Horst Dautzenberg | Mikrokapseln und verfahren zu ihrer herstellung |
US4686098A (en) * | 1984-05-14 | 1987-08-11 | Merck & Co., Inc. | Encapsulated mouse cells transformed with avian retrovirus-bovine growth hormone DNA, and a method of administering BGH in vivo |
US4680174A (en) * | 1984-05-24 | 1987-07-14 | Damon Biotech, Inc. | Induction of immune response by immunization with encapsulated antigen-producing cells |
EP0199362A3 (en) * | 1985-04-26 | 1987-10-07 | Massachusetts Institute Of Technology | System and apparatus for delayed and pulsed release of biologically active substances |
CA1310924C (en) * | 1986-04-24 | 1992-12-01 | Francis P. Mccormick | Infective drug delivery system |
CA1335798C (en) | 1988-05-17 | 1995-06-06 | Sloan Kettering Institute For Cancer Research | Retroviral vector |
US5328470A (en) * | 1989-03-31 | 1994-07-12 | The Regents Of The University Of Michigan | Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor |
DE4021050A1 (de) * | 1990-06-29 | 1992-01-02 | Akad Wissenschaften Ddr | Verfahren zur herstellung von mikrokapseln |
CA2051288C (en) * | 1990-09-14 | 2002-02-05 | Robert L. Martuza | Viral targeted destruction of neoplastic cells |
JPH06500927A (ja) * | 1990-12-13 | 1994-01-27 | アメリカ合衆国 | 高力価の組換えウイルスベクターおよび遺伝子療法に用いられる形質導入標的細胞の持続的及び連続的生産 |
WO1994029437A1 (en) | 1993-06-07 | 1994-12-22 | University Of Medicine & Dentistry Of New Jersey | Highly-efficient, self-inactivating, recombination-free, u3-free retroviral vectors |
US5688773A (en) | 1994-08-17 | 1997-11-18 | The General Hospital Corporation | Method of selectively destroying neoplastic cells |
DE69520681T2 (de) | 1994-09-02 | 2001-11-29 | Gsf - Forschungszentrum Fuer Umwelt Und Gesundheit Gmbh | Nicht selbstinaktivierende retrovirale vektoren mit gezielter expression |
ES2253754T3 (es) | 1995-06-27 | 2006-06-01 | Bavarian Nordic A/S | Celulas encapsuladas que producen particulas viricas. |
AU6987696A (en) | 1995-09-06 | 1997-03-27 | Bavarian Nordic Research Institute A/S | The use of the wap of mmtv regulatory sequences for targeted expression of linked heterologous genes in human mammary cells, including human mammary carcinoma cells |
DE69730595D1 (de) | 1996-03-27 | 2004-10-14 | Bavarian Nordic As Kvistgaard | Verkapselte zellen expremierend cytochrome p450 für die aktivierung einer medikamentenvorstufe |
-
1996
- 1996-06-24 ES ES96923905T patent/ES2253754T3/es not_active Expired - Lifetime
- 1996-06-24 SI SI9630729T patent/SI0835137T1/sl unknown
- 1996-06-24 DK DK96923905T patent/DK0835137T3/da active
- 1996-06-24 AU AU64154/96A patent/AU708273B2/en not_active Expired
- 1996-06-24 JP JP50416597A patent/JP4119952B2/ja not_active Expired - Lifetime
- 1996-06-24 DE DE69633180T patent/DE69633180D1/de not_active Expired - Lifetime
- 1996-06-24 KR KR1019970709807A patent/KR100484883B1/ko not_active IP Right Cessation
- 1996-06-24 AT AT96923905T patent/ATE309000T1/de not_active IP Right Cessation
- 1996-06-24 NZ NZ312671A patent/NZ312671A/xx not_active IP Right Cessation
- 1996-06-24 EP EP96923905A patent/EP0835137B1/en not_active Expired - Lifetime
- 1996-06-24 CA CA002222559A patent/CA2222559A1/en not_active Abandoned
- 1996-06-24 PL PL96324289A patent/PL185338B1/pl not_active IP Right Cessation
- 1996-06-24 WO PCT/EP1996/002748 patent/WO1997001357A1/en active IP Right Grant
- 1996-06-24 UA UA97126354A patent/UA65525C2/uk unknown
- 1996-06-24 CZ CZ19974195A patent/CZ286979B6/cs not_active IP Right Cessation
- 1996-06-24 PT PT96923905T patent/PT835137E/pt unknown
- 1996-06-24 IL IL12211996A patent/IL122119A/en not_active IP Right Cessation
- 1996-06-24 CN CNB961950501A patent/CN1187095C/zh not_active Expired - Fee Related
- 1996-06-24 RU RU98101362/13A patent/RU2187301C2/ru not_active IP Right Cessation
-
1997
- 1997-12-10 NO NO19975813A patent/NO321427B1/no not_active IP Right Cessation
- 1997-12-23 US US08/996,460 patent/US6776985B1/en not_active Expired - Lifetime
-
1998
- 1998-09-26 HK HK98110992A patent/HK1010139A1/xx not_active IP Right Cessation
-
2007
- 2007-11-21 JP JP2007301109A patent/JP4848348B2/ja not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
ATE309000T1 (de) | 2005-11-15 |
UA65525C2 (en) | 2004-04-15 |
ES2253754T3 (es) | 2006-06-01 |
IL122119A (en) | 2004-06-01 |
CN1187095C (zh) | 2005-02-02 |
RU2187301C2 (ru) | 2002-08-20 |
NO975813L (no) | 1998-02-23 |
AU6415496A (en) | 1997-01-30 |
DK0835137T3 (da) | 2006-03-06 |
KR19990028491A (ko) | 1999-04-15 |
NO975813D0 (no) | 1997-12-10 |
JP4119952B2 (ja) | 2008-07-16 |
NZ312671A (en) | 1999-10-28 |
EP0835137B1 (en) | 2005-11-09 |
NO321427B1 (no) | 2006-05-08 |
JP4848348B2 (ja) | 2011-12-28 |
PL185338B1 (pl) | 2003-04-30 |
CA2222559A1 (en) | 1997-01-16 |
DE69633180D1 (de) | 2004-09-23 |
US6776985B1 (en) | 2004-08-17 |
SI0835137T1 (sl) | 2006-04-30 |
WO1997001357A1 (en) | 1997-01-16 |
PL324289A1 (en) | 1998-05-11 |
CN1189104A (zh) | 1998-07-29 |
EP0835137A1 (en) | 1998-04-15 |
CZ419597A3 (cs) | 1998-03-18 |
IL122119A0 (en) | 1998-04-05 |
JP2008101011A (ja) | 2008-05-01 |
AU708273B2 (en) | 1999-07-29 |
CZ286979B6 (en) | 2000-08-16 |
PT835137E (pt) | 2004-12-31 |
HK1010139A1 (en) | 1999-06-17 |
KR100484883B1 (ko) | 2005-09-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4848348B2 (ja) | ウイルス粒子産生カプセル化細胞 | |
US6027721A (en) | Device and method for encapsulated gene therapy | |
JPH03505036A (ja) | 内皮細胞の遺伝子修飾 | |
JP2001299367A (ja) | 内皮細胞の遺伝的変性 | |
JP2001503380A (ja) | 拡散性生物学的産物を生産する細胞を含有する移植可能なアガロース―コラーゲンビーズとその利用法 | |
JP2000509249A (ja) | シトクロムp450を形質導入するレトロウイルスベクター | |
JPH11511979A (ja) | ヒト乳癌細胞を含むヒト乳腺細胞を標的として、連結された異種性遺伝子を発現させるためのwapまたはmmtv制御配列の使用 | |
JP2000500986A (ja) | レトロウイルスベクターおよび遺伝子治療におけるその用途 | |
AU724537C (en) | Method for gene transfer to the central nervous system | |
JP2002504365A (ja) | 乳房上皮細胞への遺伝子転移を伴うトランスソマチクス | |
US6540995B1 (en) | Encapsulated cells producing cytochrome P450 | |
US6537541B1 (en) | Implantation of HSV-TK retrovirus producer cells to destroy glioma | |
DE69621035T2 (de) | Retrovirale vektoren die inhibitoren der dna synthese (sdi-1) oder antisense sdi-1 nukleotid sequenzen tragen | |
US6555108B1 (en) | Implanting HSV-TK retrovirus producing cells to treat tumors | |
D’INHIBITEURS et al. | ANTISENSE SDI-1 NUCLEOTIDE SEQUENCES |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070417 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070709 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20070828 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20071121 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20071122 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20080207 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20080311 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20080317 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110509 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120509 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130509 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130509 Year of fee payment: 5 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |